Соединенные Штаты - английский - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen human 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. tisseel is effective in heparinized patients. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, can result in life-threatening thromboembolic events, and can increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions(5.3) and adverse reactions (6.2)).   do not use tisseel in individuals with a known hypersensitivity to aprotinin  (see warnings and pre

Австралия - английский - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - glucosamine sulfate potassium chloride, quantity: 995 mg (equivalent: glucosamine sulfate, qty 750 mg; equivalent: potassium chloride, qty 245 mg); bovine sodium chondroitin sulfate, quantity: 200 mg; dimethyl sulfone, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; silicon dioxide; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - helps maintain/supports healthy joint cartilage growth/development/production ; maintain/support joint health ; maintain/support joint mobility/flexibility

Австралия - английский - Department of Health (Therapeutic Goods Administration)

soul pattinson manufacturing pty ltd - glucosamine sulfate potassium chloride, quantity: 995 mg (equivalent: glucosamine sulfate, qty 750 mg; equivalent: potassium chloride, qty 245 mg); bovine sodium chondroitin sulfate, quantity: 200 mg; dimethyl sulfone, quantity: 100 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; silicon dioxide; titanium dioxide; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - helps maintain/supports healthy joint cartilage growth/development/production ; maintain/support joint health ; maintain/support joint mobility/flexibility

Австралия - английский - Department of Health (Therapeutic Goods Administration)

jnc co pty ltd t/a panax pharm t/a dr. pro - shark cartilage, quantity: 750 mg - capsule, hard - excipient ingredients: magnesium stearate; glycerol; purified water; gelatin - helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; anti-inflammatory/relieve inflammation ; decrease/reduce/relieve mild joint aches and pains ; helps enhance/promote healthy joint function ; helps enhance/promote joint health ; maintain/support joint health ; decrease/reduce/relieve mild joint inflammation/swelling ; maintain/support joint mobility/flexibility ; decrease/reduce/relieve mild joint pain/soreness ; maintain/support immune system health ; helps enhance/improve/promote immune system function

Израиль - английский - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency. haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Израиль - английский - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 50 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Израиль - английский - Ministry of Health

kamada ltd, israel - human plasma coagulation factor viii - powder and solvent for solution for injection - human plasma coagulation factor viii 100 iu/ml - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding: in patients with haemophilia a (congenital factor viii deficiency) in patient with acquired factor viii deficiency.haemoctin is not effective in controlling the bleeding of patients with von willebrond`s disease.

Израиль - английский - Ministry of Health

kamada ltd, israel - human hepatitis b immunoglobulin - solution for injection - human hepatitis b immunoglobulin 500 iu - hepatitis b immunoglobulin - hepatitis b immunoglobulin - prevention of hepatitis b virus (hbv) re-infection in hbsag and hbv-dna negative adult patients at least one week after liver transplantation for hepatitis b induced liver failure.hbv-dna negative status should be confirmed within the last 3 months prior to olt. patients should be hbsag negative before treatment start.the concomitant use of adequate virostatic agents should be considered as standard of hepatitis b re-infection prophylaxis.

Израиль - английский - Ministry of Health

kamada ltd, israel - human-rabies immunoglobulin - solution for injection - human-rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - kamrab im is indicated for passive, transient post-exposure prevention of rabies infection when given immediately to individuals in cases of contact with rabid or possibly rabid animal.

Ирландия - английский - HPRA (Health Products Regulatory Authority)

baxalta innovations gmbh - human plasma protein >90% gamma globulin - powder and solvent for solution for infusion - 0.5 g/30 m gram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for intravascular adm. - immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular administration - primary immunodeficiency syndromes (pid): congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiencies severe combined immunodeficiencies wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections children with congenital aids and recurrent infections